News & Blog

January 08, 2026 | Press Release
Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
Read More
January 07, 2026 | Press Release
Truvian Appoints Renowned Physician-Scientist and Diagnostic Innovator Dr. Michael Mina as Chief Medical and Strategy Officer
Read More
November 20, 2025 | Press Release
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
Read More
November 12, 2025 | In The News
Temple spinout rebrands as Ladder Bio, names new CEO and adds investors
Read More
November 12, 2025 | Press Release
ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer
Read More
October 21, 2025 | Blog Post
MEC Newsletter: MEC in Q3 2025 – The Road Ahead
Read More
September 25, 2025 | Press Release
Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease
Read More
August 06, 2025 | Press Release
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc.
Read More
July 31, 2025 | Blog Post
MEC Newsletter: Q2 2025 – The Future of Precision Regenerative Medicine: MEC’s Investments in Induced Pluripotent Stem Cell Therapies
Read More
July 30, 2025 | Press Release
Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity
Read More